Status: Recruiting
Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder
The primary objective of this study is to evaluate the efficacy and tolerability of Lumateperone in reducing stuttering symptoms. The following scales and samples will be collected for clinical and functional outcomes. • MLGSSS • SSS • Stuttering Severity Instrument (SSI-IV) • PHQ-9 • Barnes Akathisia • SAS • AIMS • CGI-I • CGI-S
Participants needed: 24
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: CSTrials Inc.Updated: Jul 29, 2026Locations: 1
Eligibility criteria
Subject must satisfy DSM-V criteria for childhood onset fluency disorder (stutte... [+5]
Subject has an unstable neurologic, psychiatric, or medical condition in the jud... [+8]